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Pharmacologic doses of growth hormone (HGH) or chronic HGH 
excess induce glucose intolerance and insulin resistance. Whether 
acute increments of HGH are diabetogenic as well, is not established. 
In fact, HGH is reported to have acute insulin-like effects. In this 
study, 8 postabsorptive normal subjects randomly received a HGH 
(3pg/kg/hr) or saline infusion for 8 hours. After 5 hours, a 100 gram 
oral glucose tolerance test (OGTT) was performed and HGH or saline was 
continued for the remaining 3 hours. Insulin binding to erythrocytes 
and monocytes was measured before and 4 hours after HGH infusion. 
Plasma HGH during HGH infusion rose to 25-35 ng/rnl. Before OGTT, plasma 
glucose remained unchanged (85±2 mg/dl vs 86±2 at 5 hours), FFA 
increased by 50% (p<0.01) and ketones increased by 86% (p<0.01), despite 
35% greater fasting plasma insulin levels in the HGH-infused subjects 
(p<0.005). Fasting plasma alanine decreased by 22% (p<0.005) during HGH 
infusion whereas the concentration^. of other amino acids remained 
unchanged. After OGTT, HGH-infused subjects exhibited a marked deteriora¬ 
tion in glucose tolerance. Plasma glucose rose by 30-50 mg/dl (p<0.01) 
above saline control values ( 2 hours, 162±12 mg/dl vs 121±7 and 3 
hours, 124±13 vs 85±6) and the area under the glucose response curve 
increased 2-fold (p<0.005). This occurred in the face of 2-fold higher 
insulin levels (peak values 168±33 yU/ml vs 85±26, p<0.005) in the 
HGH-infused group. Insulin binding to erythrocytes decreased by 16% 
(p<0.01), whereas, insulin binding to monocytes increased by 45%. 
Conclusions: 1) Acute physiologic elevations in HGH, which fail to 
alter fasting plasma glucose, cause glucose intolerance and hyper- 

insulinemia in man: 2) HGH-induced insulin resistance occurs in spite 
of a rise in insulin binding to monocytes. Our data suggest that HGH 
has rapid-onset insulin antagonistic effects which might contribute 
to glucose intolerance during stress. 

INTRODUCTION 
The metabolic consequences of stress in man frequently include 
deterioration of glucose tolerance, protein wasting, enhanced 
lipolysis and ketosis (1). In addition, stress can provoke elevations 
of one or more hormones, including epinephrine, glucagon, cortisol, 
and growth hormone (2). The roles of the first three of these hormones 
in mediating stress hyperglycemia have recently been examined (3). 
However, the significance of acute physiologic elevations of growth 
hormone is not known. 
The purpose of this thesis is to examine the effects of acute 
physiologic increments in growth hormone levels on carbohydrate, fat, 
and protein metabolism. As background information, the results of 
previous studies in both man and animals will be reviewed. First, 
the regulation of growth hormone secretion and the growth hormone 
response to stress will be discussed in order to establish the 
magnitude and duration of the growth hormone response and the type 
of situations in which this response might be expected to^occur. 
Then the effect of chronic elevations of growth hormone, as seen in 
acromegaly, will be considered. Finally, the effects of more acute 
growth hormone elevations on fat, glucose and protein metabolism 
will be summarized. When considering this data, it will be important 
to remember that most of it derives from studies in which supre- 




Growth hormone (GH) is a polypeptide secreted by the pituitary 
in response to a variety of physiologic and psychologic stimuli. 
Basal plasma levels in adults normally range between 1 to 5 ng/ml (A,5). 
Bursts of GH secretion occur throughout the day. The highest and most 
consistent increases in GH are seen during stage III-IV sleep with peak 
levels averaging 3A t 6 ng/ml (6). 
Basal GH concentrations have been reported to be slightly 
higher in pre-menopausal women than in men or post-menopausal 
women (7). When the magnitude of the GH response to exercise, 
arginine or insulin-induced hypoglycemia is compared at dif¬ 
ferent stages of the menstrual cycle, significantly higher 
peak GH levels are found in the high estrogen phases of the cycle 
than during menstruation (8-10). Administration of estrogen but 
not progesterone or testosterone to men also augments the peak GH 
response to various stimuli (8,9). Estrogens do not effect the 
metabolic clearance rate, distribution space, or plasma half lire 
of growth hormone (11). They seem to work by increasing the 
sensitivity of the pituitary to growth hormone releasing factor (12). 
Regulation of GH secretion is closely tied to fluctuations 
in plasma glucose concentrations. Hypoglycemia is a potent 
stimulus of GH secretion. It is well documented that insulin- 
induced hypoglycemia causes increments of 30 to 50 ng/ml in 
plasma GH that persist for several hours (5,13-16). Insulin 
by itself does not mediate this response since administration of 

glucose with insulin prevents GH increases (13). Administration 
of 2-deoxy-D-glucose, an inhibitor of intracellular glucose utili¬ 
zation, results in hyperglycemia but increased GH levels suggesting 
that intracellular glucose concentration determines the GH re¬ 
sponse (14). Conversely, glucose administration suppresses 
plasma GH concentrations in normal subjects (5,13). Results 
of animal studies localize this response to glucose receptors in 
the ventromedial nucleus of the hypothalamus (10). These receptors 
respond to absolute hypoglycemia, changing blood glucose con¬ 
centrations and intracellular deprivation of glucose (10). 
Exercise induced augmentation of GH secretion has been re¬ 
ported by several groups (5,15,17). GH has been shown to increase 
during the first hour of walking on a treadmill to 43 ng/ml and 
then to slowly decrease after that despite continuing exercise (17). 
Although blood glucose levels did not change significantly during 
this study, administration of glucose did suppress the exercise- 
induced rise in GH (.17). 
GH secretion is augmented in response to a variety of 
physical stresses. Several studies have documented a rise in GH 
during surgery (15,18-21), the magnitude and duration of which is 
proportional to the degree of surgical stress (22). Patients 
undergoing minor procedures (inguinal herniorrhaphy) generally 
fail to exhibit GH elevations, whereas patients undergoing major 
surgery (aortofemoral bypass) demonstrate peak intraoperative 
GH levels of 20 to 30 ng/ml with elevated levels in blood lasting 
up to eight days post-operation (22). Other invasive procedures 
that augment GH secretion include arterial catheterization (23) 
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and cardiac catheterization (24). 
Acute infectious diseases are associated with elevated 
GH levels. Injection of pseudomonas-derived polysaccharide 
leads to peak GH levels of 26 ± 2 ng/ml at 2 hours (25-27). 
This is not secondary to fever since injection of etiocholano- 
lone, a pyrogen, does not augment GH secretion (27). Additionally, 
the increase in GH during injection of pseudomonas polysaccharide 
is not suppresible by glucose (25). Hypersecretion of GH is 
also seen in viral illnesses. Inoculation of normal subjects 
with serum containing the sandfly fever virus results in peak GH 
levels of 5 tu 12 ng/ml (28). The rise in GH precedes the onset of 
clinical symptoms by 7 to 14 hours and persists for several 
days (28). 
Diabetic ketoacidosis (DKA) is another acute condition in 
which elevated GH levels are frequently seen (7,29-31). Unger (7) 
found that in 5 patients with DKA, GH levels ranged from 1.0 to 
70,0 ng/ml with the highest values seen in the most ketotic patients. 
Cryer and Daughaday (29) described elevated GH levels, ranging from 
13 to 215 ng/ml, in 7 of 12 patients with DKA. They saw no 
correlation between the magnitude of the GH response and the 
clinical severity, degree of hyperglycemia or depression of serum 
bicarbonate However, they did not directly measure serum 
ketones and try to correlate that with GH response. Not all 
studies have shown elevated pretreatment GH levels (32-33). 
Instead, GH levels were seen to rise after initiation of treat¬ 
ment to levels ranging from 30 to 250 ng/ml and to remain elevated 
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for at least 5 or 6 hours (29,32,33). 
Elevation in GH levels are associated with more chronic 
disease in man. Patients with Laennec’s cirrhosis have 
been shown to have abnormally high GH levels (34-36). 
Hernandez et al„(35) found increased fasting GH levels, ranging 
from 6.5 to 28 ng/ml, in 4 of 8 patients with cirrhosis. Conn 
and Daughaday (36) also reported elevated GH levels, ranging from 
4 to 33 ng/ml, in 14 of 18 patients. Those patients with normal 
GH valueshad clinically and chemically less advanced disease. 
Similar results are seen in chronic renal failure (37-39). For 
example, Wright et al*{39) found GH elevated up to 60 ng/ml in 
50 percent of their patients. In both chronic liver and renal 
disease, the abnormally high GH levels are partially due to a de¬ 
creased metabolic clearance rate and increased half life of the 
hormone (11). Additionally in liver disease hyperestrogenemia 
iaig.-t potentiate secretion (12,35). There is also evidence 
that hypothalamic regulation is altered. Paradoxical responses 
frequently occur after standard provocative testing in patients 
with chronic liver and kidney disease. It has been reported that 
GH increases after glucose administration (36-39) and fails to 
rise after tolbutamide-induced hypoglycemia (40) in such patients. 
Psychological stress is also associated with elevations in 
GH. Neurotic subjects showed significant increases in GH 
during the mirror drawing test, a standard procedure for inducing 
psychological stiess (41). In another study, a medical student 
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told that he had received an injection of a large amount of 
insulin had an increase in GH by 1 hour to 10.5 ng/ml while 
four students given the same saline injection but not told 
that it contained insulin had no rise in GH (42). Subjects 
told that they were going to see a stressful movie also showed 
significant increases in plasma GH (43). Several studies support 
the idea that elevations in GH in response to stress are re¬ 
lated more to the individuals type of defense mechanism than to 
the particular type of stress and are independent of change in 
the adrenocortical response (24,43-44). 
The secretion of GH is ultimately regulated by stimuli 
from the central nervous system. There have been several recent 
reviews detailing these interactions (4,10,45-46). In brief, 
pituitary synthesis and release of GH is under the control of the 
hypothalamus. Somatostatin has been shown to be the inhibitory 
hypothalamic factor (47). Although no hypothalamic stimulatory 
substance has yet been isolated, there is convincing evidence that 
one exists (12), In humans, the hypothalamus is thought to exert 
a predominantly stimulatory effect since hypothalamic lesions or 
section of the pituitary stalk result in lower basal GH levels 
and decreased GH response to hypoglycemia, arginine, and L-DOPA 
(4,45-46). Augmentation of GH secretion in response to insulin- 
hypoglycemia, arginine, vasopressin, exercise and surgery are 
blocked by phentolamine (20,45). Sleep related GH release is 
not effected by a or 8 adrenergic blockade. The site of action 
of neurotransmitter is thought to be the hypothalamus since 
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neuroantagonists have no effect on GH secretion induced by 
direct electrical stimulation of the hypothalamus but do block 
GH secretion after amygdaloid and hippocampal stimulation (45). 
The release of these hypothalamic factors is mediated via input 
from other areas of the brain. In the rat, electrical stimulation 
of the ventromedial nucleus, preoptic area and corticomedial 
amygdala inhibit GH secretion, whereas stimulation of the hippocampus, 
basolateral amygdala, interpeduncular nucleus and locus coerulus 
augment GH secretion (48-49). Different areas of the brain might 
be involved in control of GH at rest than during stress since septal 
lesions do not effect basal or physiologic GH fluctuations but 
do potentiate the GH response to stress (50). 
ACROMEGALY 
The effects of chronic elevations of GH on carbohydrate and lipid 
metabolism are exemplified by the derangements seen in acromc0^l^ . 
Clinically, the most obvious finding is the increased incidence of 
diabetes mellitus, which occurs in 20 to 25 percent of patients (51-52). 
The diabetes occurring in patients with acromegaly is characterized 
by relative insulin resistance and elevated fasting insulin levels 
(53-54). Additionally, the initial burst of insulin secretion 
seen after a glucose load in normal subjects and in non-diabetic 
acromegalics, is decreased in diabetic acromegalics although 
total glucose-stimulated insulin secretion may be normal (54). 
It has been suggested that the development of diabetes in acromegaly 
is a consequence of the failure of insulin secretion to keep pace 
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with the demands of insulin resistance (53,55). This hypothesis 
is supported by studies following acromegalic patients over time. 
In these studies, it was shown that individual patients with normal 
glucose tolerance demonstrated marked hyperinsulinemia, whereas 
diabetes developed when they became unable to increase their insulin 
output in response to glucose (55). 
Even in those acromegalic patients without diabetes (defined 
as fasting hyperglycemia and/or glycosuria), there is evidence 
of decreased glucose tolerance. In several studies, intravenous 
glucose tolerance tests were performed on non-insulin dependent 
patients with normal fasting blood sugars. Their rate constant for 
disappearance of glucose from the blood (K) was compared with 
that of normal subjects. Ikkos el al. (56) found that 9 of 17 
patients (53%) had a K<1, whereas all eleven controls had a K>1. 
Cerasi and Luft (57) found that 2 of 9 patients (22%) had a K<1 and 
chat the average K in acromegalics and controls were 1.3 and 1.75, 
respectively. Sonksen et al. (55). similarly found a K<1 in 
5 of 15 patients (33%) with an average K of 1.4 in the acromegalics 
and 2.6 in controls. Results of oral glucose tolerance tests are 
in agreement with the results of intravenous testing. Beck et al. (58), 
using the criteria of Fajans and Conn (glucose greater than 120 mg/dl 
at 2 hours), found abnormal glucose tolerance in 8 of 12 acromegalics 
(67%), while Fineberg et al. (59) found an average 2 hour glucose 
of 153 mg/dl in the 9 acromegalics studied and 102 mg/dl in controls. 
Since none of these studies compared patients with age-matched 

controls, they may be overestimating the frequency of abnormal 
glucose tolerance. However, it is still evident that a sig¬ 
nificant proportion of acromegalic patients with fasting euglycemia 
are less efficient in disposing of a glucose load than normal 
subjects. 
Although decreased glucose tolerance is frequently present 
in acromegaly, insulin levels are often elevated. Among 
patients with normal fasting blood sugar, 40 to 80 per cent have 
elevated fasting plasma insulin levels (55,57,59,61). Glucose- 
stimulated insulin secretion is increased approximately three¬ 
fold in 60 to 70% of patients including both those with normal 
and abnormal glucose tolerance (53,55,58,59,62). Insulin se¬ 
cretion in response to non-hyperglycemic stimuli such as arginine 
infusion or a protein meal is also elevated in acromegaly (59). 
The presence of hyperinsulinemia without hypoglycemia or 
increased glucose tolerance suggests that chronic overproduction 
of GH might lead to a state of insulin resistance. This V pcthosis 
is supported by studies in which insulin was infused into the 
brachial artery of patients with acromegaly and the arterio¬ 
venous difference in glucose concentration monitored. In these 
studies, insulin-induced increases in glucose uptake by muscle 
and adipose tissue were decreased between 33 and 50 per cent in 
acromegalic patients as compared to controls (63-65). 
Changes in the binding of insulin to its receptor on mono¬ 
cytes are seen in acromegaly (66). Monocytes taken from patients 
with acromegaly have a decreased concentration of insulin re¬ 
ceptor per cell accompanied by an increase in affinity of the 
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empty receptor. The net result is normal insulin binding at 
basal insulin concentrations but decreased binding at high insulin 
concentrations. The decrease in receptor concentration is pro¬ 
portional to the increase in basal insulin, while the decrease in 
concentration, increases in affinity, and magnitude of insulin 
resistance are all proportional to the degree of elevation in GH. 
It is not yet known wfiether the insulin resistance seen in 
acromegaly is due to direct stimulation by GH of insulin se¬ 
cretion leading to insulin-induced binding changes, by GH-induced 
inhibition of glucose utilization at a site distal to the re¬ 
ceptor leading to secondary hyperinsulinemia and resultant changes 
in binding, or to a direct effect of GH on the insulin receptor. 
Elevations in free fatty acids (FFA) are not commonly 
seen in acromegaly (55,57,58,62), and glucose administration is 
as effective in suppressing FFA levels in acromegalic patients 
t.j Jn itrols (55,57). However, studies of forearm FFA metabo¬ 
lism show an increase in output of FFA in the basal state in patients 
With acromegaly (64-65). Interestingly,insulin is as effective 
in suppressing FFA output in acromegalic patients as it is in 
controls, although it is less effective in increasing glucose 
uptake, This suggests that FFA levels are normal in acromegaly 
because elevated plasma insulin levels compensate for the effects 
pf GH on FFA release. 
lipid Metabolism 
Rats 
GH has been shown to exert both insulin-like and anti- 

insulin effects on lipid metabolism when administered acutely. 
In the rat, this has been studied mainly in hypophysectomized 
or pancreactomized animals using supraphysiologic doses of GH. 
The insulin-like action consists of an early decrease in FFA 
/ 
levels. This can be demonstrated both in vivo and in vitro. In 
vitro studies of rat adipose tissue show inhibition of basal 
lipolysis and suppression of epinephrine- induced lipolysis 
(67-68). In vivo, a fall in serum FFA levels is seen 30 to 60 
minutes after injection of GH (69-71). 
If studies last longer than one hour, a pronounced lipolytic 
effect ot GH is uncovered. By one hour after GH injection, FFA 
levels begin to rise and continue to increase for at least 5 
hours (70). Three and one-half hours after injection of 50 yg GH, 
fatty acid synthesis from glucose increases, while fatty acid uptake 
by adipose tissues decreases (69). In pancreactomized hypo¬ 
physectomized rats, ketones and FFA levels both rise (72). In 
vitro assays have found increased lipolysis by two hours after 
administration of GH (73). Dexamethasone potentiates the lipo¬ 
lytic effects of GH both in vivo and in vitro (72-74). These 
late lipolytic effects can be abolished by administration of in¬ 
hibitors of protein synthesis (e.g. cycloheximide) and RNA 
synthesis (e.g. Actinomycin D) within the first two hours after 
exposure to GH (69,73,75). These inhibitors also prolong the 
early anti-lipolytic effects of GH (76). 
Studies examining the effects of GH on hepatic lipid 
metabolism have yielded conflicting results. Lotspeich & 

Peterson (77) injected rats with 1 mg of GH per day for four days 
then gave 5 mg of GH/100 gm body weight on the fifth day and 
sacrificed the rats 2 hours later. Isolated liver slices 
showed greatly increased synthesis of acetoacetate and increased 
liver fat. Penhos et al. (78) perfused rat livers with 0.5 mg/ml 
of GH for 90 minutes and found increased hepatic uptake of trigly 
cerides and FFA but no increase in ketone production. Chernick 
et al. (72) perfused rat livers with 5 yg/ml GH for 90 minutes 
and saw no increase in hepatic uptake of FFA. cr ketone production 
The differences between these studies probably reflect the 
variations in dose of GH and duration of exposure. The study 
using the most physiologic dose showed no effect of GH on 
either hepatic uptake of FFA or hepatic ketone production (72). 
Dogs 
Data in dogs are also consistent with an early hypo- 
lipodemic action of GH, As was ca:° in rats, these studies 
used pharmacologic quantities of gH. An early decline in FFA 
levels after injection with GH is followed by a 4-fold rise in 
FFA and glycerol levels within three hours as well as an increase 
In the turnover of FFA and in the percentage of total respiratory 
CO^ derived from FFA (79). Of interest the observation that 
the rise in FFA levels only lasts for five to ten days. After 
that, FFA levels return to baseline despite the continued ad¬ 
ministration of GH (80-82), The return to baseline is not due 
to depletion of fat stores since norepinephrine stimulated lipo- 
lysis can still occur (79). It is also not due to increases in 
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plasma insulin since insulin levels increase several days be¬ 
fore the decline in FFA levels is seen (79). 
Humans 
In adult humans, GH exerts effects similar to those in¬ 
duced in animals. There have been several reports of 
an early decrease in FFA levels following administration of 
large doses of GH. For example, 4 mg GH intravenously causes 
a 21 per cent fall in plasma FFAs at one hour (83), while 10 mg 
GH intravenously causes a 33 percent decline in plasma FFA 
levels by n minutes due to a decrease in output (84). 
Increases in plasma FFA levels are seen- 2 to 4 hours after 
injection of GH. Several groups have found approximately a 100 
percent increase in FFA levels after injection of 4 to 8 mg of 
GH (80,84-87). GH-induced increases in FFA levels are inhibited 
by the administration of glucose (80) and by inhibitors of lipo- 
<=i* h as nicotinamide (87) and 5-methylpyrazole-3-carboxylic 
acid (86). Insulin is as effective in suppressing lipolysis 
in subjects injected with GH 4 hours before insulin injection or 
in subjects infused simultaneously with insulin and GH as it is 
in control subjects (64,84). 
The effect of GH on peripheral uptake and output of FFA 
has been examined in studies where GH was infused into the 
brachial artery of normal volunteers. Changes in the arterial 
minus deep venous FFA concentrations were taken as representative 
of muscle metabolism and changes in arterial minus superficial 
venous FFA concentrations were taken as representative of adipose 
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tissue metabolism. When arterial GH concentrations of 300 
ng/ml were achieved, an immediate increase in FFA uptake 
by muscle was seen followed by a sustained increase in FFA 
output from adipose tissue beginning at forty minutes (64,88). 
When lower concentration of GH were infused (28.4 ng/ml to 
200 ng/ml) however, no effect of GH on muscle or adipose tissue 
lipid metabolism was seen during the 90 minute duration of 
the study (83). The discrepancy between these studies may 
be due to differences in the dose or duration of exposure to GH. 
The effect of GH on ketogenesis in humans has been studied 
only in insulin dependent diabetics (89). In this experiment, 
diabetic subjects were divided into 3 groups. One group was given 
1 mg of GH 12 hours before the study. The second group was infused 
with 4 yg/kg GH for 1 hour at the start of the study. A third group 
served as controls. All 3 groups received heparin in order to 
elevate plasma FFA levels so that the ketogenic effects of GH 
could be examined independently of its lipolytic effect. Similar 
FFA levels were achieved in all three groups but the group treated 
with 1 mg GH 12 hours earlier had significantly greater increases in 
ketone bodies. The authors concluded that GH exerts ketogenic activity 
that is delayed at least 60 minutes in onset. However, it is difficult 
to ascribe this effect to GH, since GH levels had returned to 
baseline well before the heparin injection was given. Also, 
the group that had increased ketogenesis had significantly lower 
insulin levels. Unless GH itself caused the decreased insulin 

levels, it is unlikely that GH was responsible for the increased 
ketogenesis. 
Another study examined the role of basal GH levels in 
insulin-dependent diabetics (90). In this study, somato¬ 
statin was given to suppress glucagon and GH secretion. When 
GH and insulin were infused along with the somatostatin,no 
effects were seen. However, when GH was infused to achieve a 
plasma concentration of 6 ng/ml in the absence of insulin, 
levels of FFA, glycerol and 8-hydroxybutyrate began to increase 
by 1 hour and were significantly higher than controls at 4 to 6 
hours. The authors concluded that basal levels of GH can augment 
lipolysis and ketogenesis only in the absence of insulin. 
No study has examined the effects of physiologic 
increment in GH, such as those seen during various types of 
stress, on lipid metabolism in normal subjects. 
Carbohydrate Metabolism 
Rats 
The dichotomy between the early and late effects of GH 
on lipid metabolism are also apparent in regard to glucose 
metabolism. In the normal and hypophysectomized rat, injection 
of GH leads to a reduction in blood sugar within 20 minutes 
(71,77,91). In vitro incubation of rat muscle,adipose or kidney 
tissue with GH results in an increase in glucose uptake and 
oxidation within 20 to 60 minutes (68,91-93). These early 
effects can be duplicated by incubation of tissue with high 
concentrations of glucose suggesting that they might be due to 
an increase in cellular uptake of glucose (93). Increased 

cellular uptake of glucose could be mediated by changes in 
insulin secretion or degradation or in the tissue response to 
insulin. The importance of insulin in the acute hypoglycemic 
action of GH is supported by the observation that no acute hypo¬ 
glycemic effect is seen after GH injection into insulin-deplete 
diabetic rats (94). Although plasma insulin levels are not 
elevated within the first hour after exposure to GH, insulin 
degradation has been reported to transiently decrease (91) 
and insulin release from the pancreas of hypophysectomized 
rats (93; and normal rats (96) has been reported to increase. 
Exposure to GH for longer than 1 to 2 hours causes hyper¬ 
glycemia and decreased glucose utilization in the rat. Three 
hours after exposure to GH, it is possible to show decreased glucose 
utilization in adipose tissue (69). Four days of treatment with 
GH and dexamethasone result in glycosuria in partially pan- 
creatomized rats (98). Twelve days of GH injection cause in¬ 
creases in blood glucose and decreased glucose uptake in 
vitro in hypophysectomized rats (99). These later hyperglycemic 
effects can be prevented by exposure to inhibitors of protein and 
RNA synthesis. These also prolong the early hypoglycemic actions 
of GH (93). 
Prolonged exposure to GH in rats has been reported to cause 
hyperinsulinemia and insulin resistance (100). Rats implanted 
with a GH-secreting tumor have a 5-fold increase in fasting 
insulin levels, increased pancreatic islet volume and insulin 
content and increased glucose stimulated insulin secretion in 

vitro. This is accompanied by decreased utilization of glu¬ 
cose by diaphragm and adipose tissue in vitro (100). Conversely, 
islets taken from hypophysectomized rats have a decreased 
insulin content and release which returns towards normal after 
3 days of treatment with GH (101). Injection of 1 mg GH twice 
a day for 5 days into normal rats results in a 2 fold increase 
in plasma insulin levels and a 10 mg/dl increase in blood sugar 
(102). This is accompanied by a decrease in the concentration 
of insulin receptors on hepatic membranes a^d an increase in the 
affinity of the empty receptor (102), changes similar to these 
seen in monocytes of patients with acromegaly (66). 
Dogs 
In the dog GH causes transient hypoglycemia in hypo¬ 
physectomized animals but not in normal dogs. Tnis is accompanied 
by an increase in glucose uptake (79). Whether insulin is necessary 
for the hypoglycemic effect in dogs is not clear,since,in acutely 
pancreactomized dogs,GH also causes transient hypoglycemia (103). 
This is the opposite of the situation in the rat. The differences 
may be due to the presence of residual insulin in the acutely 
pancreactomized dogs. 
More prolonged exposure to GH in both normal and hypo¬ 
physectomized dogs causes increases in blood glucose and insulin 
(79, 82,104-105). The hyperglycemic reaction is dependent upon 
the nutritional status of the dog. Dogs that have been fasted 
for four to five days before receiving GH maintain a normal 
blood glucose,but this is in the presence of marked hyperin- 
sulinemia and insulin resistance (79). The hyperglycemia is 

due to a decrease in peripheral glucose clearance and an 
increase in the hepatic release of glucose (79,82,105). 
Humans 
In normal humans, pharmacologic doses of GH have been 
shown to induce a transient decrease in blood glucose of 
approximately 10 mg/dl within the first hour after exposure 
to GH (83-84, 106-107). This has been attributed to a de¬ 
crease in glucose output (84,107). Very early after GH 
administration (10 minutes), it can be shown that glucose 
utilization as measured by the intravenous glucose tolerance 
test (IVGTT) increases by 30 percent (62,85). 
Longer term administration of pharmacologic doses of GH 
causes increases in blood glucose only in hypopituitary patients 
(53) and obese patients during a period of starvation (108). 
However, results of IVGTT in normal subjects reveal a 50 per 
cent decline in glucose utilization 2 to 5 hours after GH 
injection (62,85-87). Glucose-stimulated insulin release has 
been reported to increase (62,106), to remain unchanged (87), 
and to decrease (109) following GH administration. 
To evaluate the effect of acute administration of GH on 
peripheral glucose metabolism, GH was infused into the brachial 
artery of normal subjects while arteriovenous differences in 
glucose concentration were measured. When pharmacologic doses 
of GH were infused, an immediate 50 percent reduction in glucose 
uptake by muscle and adipose tissue was seen (64,88). When more 
physiologic doses were infused for 30 minutes, a 30 percent decrease 

in glucose uptake into muscle tissue was seen (83). In 
neither study was any early insulin-like action observed. 
There is some evidence that short term GH infusions can 
lead to a state of insulin resistance. Infusion of GH into 
the brachial artery along with insulin blocks the effects of 
insulin on glucose uptake (64, 65). Giving an insulin infusion 
four hours after 5 mg of GH results in attenuation of insulin 
induced increases in glucose uptake (84). Amino acid-stimu¬ 
lated insulin release is 2-fold greater in GH treated sub¬ 
jects than in controls but does not cause any change in 
blood sugar (110). Finally, obese subjects in the fed state 
given GH have increased insulin levels but normal blood sugars 
(108). 
Most of the previously cited studies were done using 
pharmacologic doses of GH. An attempt to examine the consequences 
of physiologic fluctuations in GH levels was made by Yalow et al. 
till). They provoked increases in plasma GH by giving a 100 
gram oral glucose load to normal subjects. Plasma GH began to 
rise, in response to falling blood glucose levels, 3 to 4 hours 
after the oral glucose load was given and peaked at about 13 ng/ml 
at 4 to 5 hours.Six hours after the original glucose load, a repeat 
100 gm oral GTT was performed. In those subjects who had shown 
an elevation in GH in response to the first glucose load, the 
second GTT showed significantly decreased glucose tolerance and 
markedly increased glucose-stimulated insulin release. Those 
subjects who did not augment their GH secretion in response to 
the original glucose load had no deterioration of glucose 

tolerance during the second test. This seems to indicate 
that physiologic elevations in plasma GH levels cause a deterior¬ 
ation in glucose tolerance and increased insulin secretion. However, 
when the oral GTT was repeated 4 hours after the initial glucose 
load, at the time of the peak GH response, glucose tolerance 
was only slightly impaired and glucose-stimulated insulin 
secretion was not increased. Finally, repeating the oral GTT 3 
hours after the initial glucose load resulted in improved glucose 
tolerance and decreased insulin secretin The major difficulty 
in interpreting this set of experiments cnar many factors 
other than GH are responsive to changes in glucose levels. It is 
likely that fluctuations in the plasma levels of epinephrine, 
norepinephrine, cortisol and glucagon occurred CH2) and also 
influenced the results. 
In another series of studies, GH was infused into healthy 
subjects for 30 minutes at diffciart dc es (109,113-114), The 
two lowest doses, 5 and 10 yg/kg, resulted in post-infusion GH 
concentrations of 20 and 48 ng/ml, leyels simulating those 
seen during stress. Blood glucose was found to decrease slightly 
but significantly only in the group receiving a yg/kg GH infusions, 
not in the group that received 10 yg/kg CII infusions. However, 
both groups showed significant decreases in basal plasma insulin 
that were apparent by 15 minutes after the start of the GH in¬ 
fusion and lasted up to 60 minutes after the infusion ended (109). 
There was no correlation between the timing and the magnitude of 
the changes in insulin and glucose. When glucose utilization was 

estimated by the IVGTT, it was found that glucose tolerance 
measured at the end of a 30 minute 10 yg/kg GH infusion had 
deteriorated significantly (113). However, glucose tolerance 
continued to deteriorate even further over the five hours 
following the end of the infusion despite the fact that GH 
levels had returned to baseline by 1 hour after the end of the 
GH infusion (109,113). Glucose-stimulated insulin secretion 
was unaffected by infusion of physiologic doses of GH in this 
study (113), but in a later study which divided the subjects into 
3 groups, mild diabetics, low and high insulin responders, 
glucose-stimulated insulin secretion was found to decrease in the 
diabetic and low insulin responders (114). Glucose tolerance, 
however, decreased in all three groups. There are several 
difficulties in interpreting these studies. One problem is that 
GH concentrations were not kept constant during the study period 
making it unclear whether decreased glucose tolerance and suppress 
of insulin release were in fact due to the GH administered 5 hour 
earlier. Another difficulty is explaining the suppression of 
insulin levels since most of the data available in humans and 
animals support the hypothesis that GH leads to increased levels 
of insulin. There is no information available on the effects 
of a sustained increase of GH to levels seen normally during 
stress on insulin secretion, glucose levels, and glucose tolerance 
Protein Metabolism 
Animals 
It has been known that GH influences protein metabolism 
since the early studies of Evans and Long (115) and Teal 
and Cushing (116) demonstrated increased growth of normal rats 

and dogs treated with pituitary extracts. Later it was 
discovered that treatment of normal or hypophysectomized 
animat with pharmacological doses of GH caused a decrease 
in both blood amino nitrogen levels and urinary nitrogen 
excretion that is apparent by one hour after exposure to 
GH (117, 118) and lasts during several weeks of GH therapy. 
The effects of GH on protein metabolism have recently been 
reviewed (119). 
One action of GH is to increase the rate of uptake of 
amino acids into skeletal muscle, cardiac muscle and liver. 
This occurs after a 30 to 60 minute lag period and disappears 
after 3 to 4 hours (119). Administration of inhibitors of 
protein synthesis such as puromycin and cycloheximide or 
inhibitors of RNA synthesis such as Actinomycin D prolong the 
stimulatory action of GH on amino acid uptake (119) . In vitro 
studies using radioactively labelled amino acids have shown 
tnut GH increase the uptake of glycine, alanine, serine, 
threonine,histidine, proline, tryptophan, asparagine and 
glutamine but does not effect the rate of uptake of valine, 
phenylalanine, leucine, methionine, tyrosine, lysine, arginine, 
glutamate or aspartic acid (120). 
It has been suggested that augmentation of amino acid 
transport is mediated by GH-induced increases in plasma insulin 
(119). This is unlikely since insulin levels do not increase 
until after the peak increase in amino acid uptake has occurred. 
In addition, increased uptake occurs after exposure to GH in 

vitro as well as in vivo (119). Finally, inhibition of 
phosphodiesterase with theophylline or caffiene blocks GH 
induced changes in animo acid transport but does not affect in¬ 
sulin-induced transport changes (119). 
GH also acts to increase the rate of protein synthesis 
in muscle and liver (119). This effect occurs after a 30 
minute lag period but,unlike the increase in amino acid uptake 
persists for at least several days. In vitro studies using 
labelled amino acids have shown a 30 to 50 percent increase in 
incorporaf rm of glycine, alanine, serine, proline, histidine, 
threonine, methionine, tryptophan, tyrosine, leucine, valine, 
phenylalanine, lysine and arginine into protein (120). Thus 
different amino acids are involved in transport and synthetic 
effects of GH. These two processes were also shown to be 
separate in a study in which amino acid uptake was blocked by 
removal of Na from the incubation medium (121). Under these 
conditions, stimulation of protein synthesis is unaffected. 
GH causes increased .protein synthesis ,at least in part, by 
enhancing the catalytic activityof ribosomes (122) and increasing 
the number of ribosomes (123). The changes in ribosomal activity 
reach a maximum at 18 to 24 hours after exposure to GH. 
Salmon and Duvale (124) suggested that somatomedins, 
not GH, are the ultimate stimulus of increased protein 
synthesis in muscle. However ,this was disputed by Kyosto and 
Nutting (125) who found that while protein synthesis began to 
increase after 30 minutes, somatomedin levels in blood did not 
begin to increase for 6 to 24 hours after administration of GH. 

This does not exclude the possibility that somatomedins mediate 
the prolonged duration of the increase in protein synthesis. 
The above studies on amino acid uptake and protein syn¬ 
thesis have all been performed on hypophysectomized animals. 
It has not been possible to demonstrate any changes in uptake 
or synthesis in normal adult rats even with administration of 
pharmacologic quantities of GH. Recently, enhancement of 
both these processes has been found after in vivo and in vitro 
GH treatment in young (17 to 18 day) normal fats (126-128). 
The characteristics of enhanced amino ana transport were similar 
to those observed in hypophysectomized animals,whereas only a 
transient increase in protein synthesis was found. 
Humans 
The effects of GH on protein metabolism in human sub¬ 
jects has not been studied as extensively as in animals. It 
is known that treatment of hypo--' tuifry patients and normal 
subject with large doses of GH results in decreased urinary 
nitrogen excretion, decreased plasma amino nitrogen and a 
positive nitrogen balance (129-131). Normal subjects are less 
sensitive than hypopituitary patients to GH administration (132). 
The response of obese subjects treated with large doses of GH 
for 5 days is dependent upon their nutritional status (108), 
Patients in the fed state respond to GH by decreasing urinary 
excretion of urea and ammonia with a resultant positive nitrogen 
balance. After prolonged starvation of obese subjects, GH 
causes a 50 percent decrease in urea excretion but this is 
balanced by a 50 percent increase in ammonia excretion so 
that there is no net change in nitrogen balance. The authors 

concluded from this that GH does act to decrease protein 
catabolism,but, in starvation,the lipolytic and ketogenic effects 
of GH result in increased urinary acid secretion in the form 
of ammonia and oppose the protein-sparing effects of GH. 
The effect of GH on specific amino acid levels in 
blood has been examined in normal patients after injection of 
4 mg GH intravenously (133). Leucine decreased by 50 percent 
30 minutes after GH injection and levels remained depressed for 
the 4 hour duration of the study. Methionine, tyrosine, and 
alanine levels fell significantly by 30 mnutes but returned 
to baseline by 2 hours. Decreases in histidine were not seen 
until 2 hours after GH exposure. Glycine levels actually 
rose at 30 and 60 minutes and then returned to baseline. No 
other amino acids were studied. The acute effects of physiologi 
increments in GH on amino acid levels in normal subjects are 
not known. 

MATERIALS AND METHODS 
Subj ects 
Studies were performed on 8 healthy subjects, 5 male and 3 
female, with a mean age of 26.4 ± 4.2 years. All were within 
15 percent of ideal body weight (Metropolitan Life Insurance 
Tables, 1959). Details are in Table 1. Subjects consumed weight- 
maintaining diets containing at least 200 gm of carbohydrate and 
were taking no drugs. All had negative primary family histories 
for diabetes and none had an elevated fasting plasma glucose. 
The subjects were informed of the nature, purpose and possible risks 
of the study before their written, voluntary consent to 
participate was obtained. Prior approval for these investigations 
was obtained from the Yale Human Investigations Committee. 
Experimental Design 
Studies were begun in the morning after a 12 to 15 hour 
overnight fast. A polyethylene catheter was inserted into en 
antecubital vein for blood sampling and in the contralateral vein 
for administration of human growth hormone (HGH). Two experimental 
protocols were employed in each subject. In the'■first, HGH, at 
a dose of 3 yg/kg/hr, was infused for 8 hours at a flow rate of 
14.4 ml/hr by a Yale Digital Infusion Pump. HGH (obtained from the 
National Pituitary Agency) was prepared by first dissolving it in 
10 ml of distilled water and then diluting it into a larger volume 
of 0.9% NaCl. In the second study, physiologic saline, rather than 
HGH, was infused for 8 hours under identical conditions. After 
either HGH or saline had been infused for 5 hours, a 3 hour 100 gm 
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oral glucose tolerance was begun (Dexerol). The first four sets of 
studies were performed in random order. In the second four sets of 
experiments, the saline infusions were performed first because of 
concern about possible long term effects of HGH infusion. 
Some subjects also participated in a third study in which 
0.9% NaCl or 3 yg/kg/hr HGH were infused for 5 hours for measurement 
of insulin binding to monocytes and erythrocytes. Individual studies 
were separated by a minimum of 48 hours and a maximum of 14 days. 
No subject experienced any unpleasant side effects. 
SAMPLING PROCEDURES 
Blood fcr glucose measurement was drawn at times t=-15,0,30,60,120, 
180 and 240 minutes and at 15-30 minute intervals thereafter. Samples 
were immediately centrifuged and the plasma used for assay of glucose. 
Samples for plasma immunoreactive insulin were collected in heparin¬ 
ized tubes at the same time intervals as the glucose samples were 
collected. 
3ml of blood was added to tubes containing 0.3ml Trasylol and 
10.5 mg EDTA for determination of immunoreactive glucagon. Samples were 
obtained at t=-15,0 and 60 minutes and every 60 minutes thereafter up 
to 480 minutes. 
Samples for measurement of FFA were collected in heparinized tubes 
at t=-15,0 and 60 minutes and every 60 minutes thereafter up to 300 minutes. 
Equal volumes of blood were mixed with 6.0% perchloric acid for 
determination of acetoacetate and g-hydroxybutyrate. Samples were 
obtained at t=-15,0 and 60 minutes and every 60 minutes thereafter up 
to 300 minutes. 
Samples for measurement of plasma amino acids were obtained in 
heparinized tubes at the same time intervals as the ketone samples were 
obtained. The plasma was deproteinized with 10% sulfasalicylic acid. 

Plasma for measurement of HGH was obtained at t=-15,0,60,180 
and 300 minutes and at 30 to 60 minute intervals thereafter. 
At t=0 and 240 minutes blood was collected in heparinized 
tubes for measurement of insulin binding to monocytes and ery¬ 
throcytes . 
Glucose and insulin binding assays were performed on the 
day of the study. All other samples were stored at -20°C until 
used for analyses. 
CHEMICAL ANALYSES 
Plasma glucose was assayed by the glucose oxidase method 
(134) on a Beckman Glucose Analyzer (Beckman Instruments, 
Fullerton, California). 
Plasma immunoreactive insulin was determined by radioimmuno¬ 
assay using talc to separate bound from free insulin (135). 
Plasma immunoreactive glucagon was measured by radioimmuno¬ 
assay using the Unger 30K antibody (136). 
Plasma growth hormone was measured by radioimmunoassay (137) 
by the Yale New Haven Hospital Clinical Immunology Laboratory. 
8-hydroxybutyrate and acetoacetate concentrations in blood 
were determined by the method of Williamson, Mellanby, and Krebs 
(138). 
FFA levels were determined enzymatically by a modification of 
the method of Dole (139). 
Plasma amino acids were assayed by automatic ion-exchange 
chromatography (140). This method measures neutral and acidic 
but not basic amino acids. 

Insulin binding to monocytes was determined using ^^1- 
monoiodoinsulin (141). Monocytes were isolated from 50 ml of 
whole blood and incubated for 3 hours with 0.2 ng/ml ^^i-insulin 
in the presence and absence of unlabelled porcine insulin. The 
125 
specific binding of I-insulin was calculated by subtracting 
nonspecific binding (^2“*I-insulin bound in the presence of un¬ 
labelled insulin) from total 125I-insulin binding (125I-insulin 
bound in the absence of unlabelled insulin), Total binding 
capacity was calculated by Scatchard analysis (142). 
Insulin binding to erythrocytes was determined by the method 
of Gambhir, Archer, and Carter (143). Erythrocytes were isolated 
from 10 ml of blood using a Ficoll-Hypaque gradient and incubated 
IOC 
for 2.5 hours with x xI-insulin in the presence and absence of 
unlabelled insulin. RBC-bound insulin was separated from free 
insulin using dibutyl phthalare. Specific binding and total 
receptor capcity were calculated as in the monocyte binding studies. 
STATISTICAL METHODS 
All values represent the mean of duplicate determinations of 
each sample. Data is given as the mean - standard error. Analyses 
was performed using the Students T-test. The paired t-test was 
used to compare results from GH infusion with results from the 




Subject Age Sex Height 
(cm) 
V.P. 18 M 180 
N.R. 38 F 157 
D.F. 35 M 183 
L. S. 22 F 170 
T.B. 18 i'i 175 
T.W. 34 M 175 
C.C. 23 F 180 
B. 0. 23 M 188 













Growth Hormone Levels 
Mean preinfusion GH levels were similar in both the saline and 
GH infusion studies (saline, 2.2±0.8 ng/ml vs GH, 1.8±0.3 ng/ml, p>0.05). 
As can be seen in Figure 1, GH levels increased rapidly during the 
infusion of GH, reaching a stable plateau within 2 hours. The 
mean plateau value was 35.2±4.4 ng/ml. Individual preinfusion and 
plateau GH concentrations are shown in Table 2. 
Effect of GH on Basal Substrates 
The first 5 hours of these studies. t'ofnre the start of the oral 
glucose tolerance test, is considered the basal period. Mean 
basal glucose concentrations during GH and saline infusion are given 
in Table 3. Glucose levels remained nearly constant throughout 
the basal period and there was no significant difference between the 
GH and corresponding saline control glucose levels. 
Figure 2 demonstrates the -linages in FFA and ketone levels that 
occurred during the infusion of GH. FFA levels (491±43yM before GH 
infusion) increased by 76% in the GH group (to 866±74yM) whereas 
they increased by only 25% (to 576±66yM) in th^ fasting saline 
control group. The differences between the corresponding saline 
and GH FFA levels were statistically significant after 180 minutes 
(p<0.05-0.005). Similiarly, blood ketone levels (0.110±0.08mM before 
GH infusion)- increased 86% during the GH infusions and were signifi- 
canly higher than the corresponding saline control values at 180 
minutes (p<0.05) and 300 minutes (p<0.01). 
In 3 subjects, 11 different amino acids were measured during the 

infusion of GH (Table 4). Since in these studies only plasma 
alanine appeared to change substantially, we elected to further 
evaluate this question in all subjects by measuring alanine using 
a short column technique. The latter studies also provided data 
on glycine, valine, leucine, and isoleucine which is included in 
Table 5. These data show that alanine decreased by 22% during the 
GH infusion and was significantly lower than preinfusion values at 
240 minutes Cp<0.001) and 300 minutes (p<0.005). In addition, 
there was a small decline in plasma glycine (8%, p<0.05), whereas 
the concentrations of the branch chained amino acids(valine, leucine, 
and isoleucine) remained unchanged. There were no significant 
changes in amino acid concentrations during the control saline 
infusions. 
Effect of GH on Basal Hormone Levels 
As shown in Table 3, plasma insulin levels were 35% greater in 
the GH-infused subjects than in the saline controls at 5 hours. 
Figure 3 demonstrates 0 and 5 hour plasma insulin levels in the 
saline and GH groups. It is apparent that insulin levels tended to 
increase during the GH infusions whereas they tended to decrease 
during the saline infusions. The difference between the two groups 
became significant by 5 hours (GH, 16.3±l.lyU/ml vs saline, 12.1t0.9 
yU/ml, p<0.005). In contrast, basal plasma glucagon levels de¬ 
creased slightly in control and GH studies and never differed 
significantly between groups (Table 3). 
Effect of GH on the Response to a Glucose Load 
The GH response to a 100 gram oral glucose load is shown in 
Figure 1. As expected (5,13), mean GH levels tended to fall in the 
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saline control subjects from 4.5±1.7 ng/ml at 300 minutes to 1.87 
±0.5 ng/ml by 60 minutes after ingestion of glucose. However, these 
changes were not statistically significant. After 60 minutes, GH 
levels returned to values seen prior to glucose. In the GH-infused 
subjects, plasma GH remained unchanged. 
Figure 4 demonstrates the mean glucose and insulin responses to 
the 100 gram oral glucose load. GH treatment resulted in marked 
deterioration in glucose tolerance with plasma glucose levels 30 to 
50 mg/dl above the corresponding saline '•'or.tiiol values from 90 
minutes after glucose administration until i tne end of the study 
(90 min., 170+11 mg/dl vs 127±11 mg/dl, p<.0.005; 120 min., 162±12 mg/dl 
vs 121±7 mg/dl, p<0.01; 180 min., 124±13 mg/dl vs 85±6 mg/dl, p<0.05). 
The incremental area under the glucose curve during the glucose 
tolerance test was increased by 85% in the GH-treated subjects as 
compared to the saline controls (11078±1571 mg/dl/180 min. vs 5885 
±1069 mg/dl/180 min., p<0.005). 
The decreased glucose tolerance occurred despite an increase in 
insulin secretion. Mean peak insulin levels were 2-fold higher in 
GH-treated subjects (168±34 yU/ml vs 86±18 yU/ml, p<0.005) and the 
incremental area under the insulin curve was 82% greater than in 
the saline control (18404±3306 yU/ml/i8C min. vs 10145±2272 yU/ml/180 
min., p<0.005). Insulin levels in the GH-infused subjects were 
significantly higher than in the saline controls at 60 minutes 
(103±19 yU/ml vs 86±18 yU/ml, p<0.005), 120 minutes (168±34 yU/ml vs 
80±22 yU/ml, p<0,005), and 180 minutes (128±28 yU/ml vs 41±7 yU/ml, p<0.02) 
after glucose ingestion. The time course of the insulin response also 
differed between groups. During the saline infusions, peak insulin 
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levels occurred at 60 minutes whereas during the GH infusions, 
insulin levels did not peak until 120 minutes after glucose 
administration. 
Figure 5 compares individual 120 minute glucose and insulin 
levels in the GH and saline groups. It shows that 2 of 8 subjects . 
(open circles) did not have significantly different glucose levels 
in the GH and saline infusions but that all subjects had elevated 
insulin responses after GH infusion. The glucose and insulin 
responses of the 2 subjects whose glucose tolerance did not de¬ 
teriorate after GH treatment are descru'K ’ more detail in Figure 6. 
Although the total area under their glucose curves remained unchanged, 
the area under their insulin curves increased by 67% (subject D.F.) 
and 73% (subject L.S.). 
During the glucose tolerance test, plasma glucagon decreased by 
30% in the GH-treated subjects and by 12% in the saline controls 
(Table 6) . The differences between th<_ two groups never attained 
statistical significance. 
There was no correlation between the absolute decrease in 
glucose tolerance and the absolute increase ir. the insulin response 
(R=-0.2, p>0.05) or between the percentage changes in glucose and 
insulin (R= 0.3, p>0.05). Nor was the?:° any relationship between the 
magnitude of the plateau GH elevation and the glucose (R=-0.07, p>0.05) 




Individual Growth Hormone Levels 
0 
Minutes Plateau 
HGH V.P. 2 44 
ng/ml N.R. 1 28 
D.F. 1 40 
L.S. 3 25 
T.B. 1 25 
T.W. 2 35 
C.C. 2 25 
B.O. 1 60 
Mean 
1 f, 
-L * v-/ 
SEM 0.25 4 

FIGURE 1 
EFFECT OF GROWTH HORMONE INFUSION 
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FIGURE 2 AO 
EFFECT OF GROWTH HORMONE INFUSION 
ON BASAL LEVELS OF 
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EFFECT OF GROWTH HORMONE ON 
GLUCOSE AND INSULIN RESPONSE 
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FIGURE 6 46 
INSULIN RESPONSE IN 2 SUBJECTS 
WITHOUT HGH-INDUCED 
GLUCOSE INTOLERANCE 
Subject L.S. Subject D.F. 
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The current data demonstrate that acute physiologic 
elevations of plasma GH levels, which do not affect basal 
plasma glucose concentrations, result in marked deterioration 
of glucose tolerance. In addition, GH infusion causes elevations 
in basal FFA and ketone levels, in the face of a rise in plasma 
insulin concentration, as well as a reduction of plasma alanine 
levels. The magnitude of the elevations in GH achieved during the 
GH infusions were in the range of those commonly seen during 
surgery (5,18-22), infection (25-28), exercise (5,15,17), 
diabetic ketoacidosis (7,29-33), uremia (37-39) and cirrhosis 
(34-46). Although in some situations only transient GH elevations 
are observed (17,19), in others, such as severe trauma (145), 
major surgery (18,22) and diabetic ketoacidosis (29,32), GH 
often remains elevated for more prolonged periods of time, ranging 
from 5 to 6 hours (29) to several days (18,22,145). Thus, it is 
likely that our findings are relevant to the metabolic 
seen during severe stress. 
After an overnight fast, plasma glucose concentrations are 
Maintained at a constant level by release of glucose from the liver 
at a rate equal to the rate of glucose utilization by peripheral 
tissue (146). Approximately 70% to 75% of hepatic glucose release 
is derived from gluconeogenesis (146). In this study, plasma 
glucose concentrations did not differ significantly in the GH- 
treated subjects as compared to the saline controls. In contrast, 
several groups have reported a slight decrease in plasma glucose 
levels 30 to 60 minutes after administration of pharmacologic 
quantities of GH (83-84, 106-107). The present data support the 

view that acute hypoglycemia is a pharmacologic, not a physiologic, 
action of GH and that physiologic elevations of GH do not have a 
major effect on basal hepatic glucose output or on basal peripheral 
glucose utilization. 
Despite the maintenance of normal basal glucose levels 
during the infusion of GH, glucose tolerance was significantly 
reduced. This is similar to the findings in studies using 
pharmacologic quantities of GH (62,85-87) and to the findings 
in acromegaly (55-59) of deterioration in glucose tolerance in 
many, but not all,subjects. It is of interest in the regard, 
that in two of our patients,GH had little effect on glucose 
tolerance, although insulin secretion was enhanced in these 
individuals. 
In normal postabsorptive subjects, a 100 gram oral glucose 
load is distributed throughout the body as follows: 1) Less 
_L n 57 remains in the glucose space after 3 hours, 2) 25% is 
utilized by noninsulin-dependent tissue, such as brain and renal 
medulla, to meet ongoing metabolic needs, 3) 15% is utilized by 
insulin-dependent peripheral adipose and muscle cells, and 4) 
55% to 60% is taken up by the liver (146). In addition, hepatic 
glucose production decreases to 75% to 80% below basal levels (147). 
GH could conceivably effect any one of the above steps, 
although there is no evidence to suggest that it alters the space 
of glucose distribution or that it effects the utilization of 
glucose by insulin-independent, glucose-dependent tissue like 
the brain. Adamson et al.(107) observed that pharmacologic doses 
of GH actually inhibited splanchnic glucose production by 30% to 

40% in fasting subjects and had no effect on the hepatic response 
to an intravenous glucose load. These findings suggest that the 
effect of GH to decrease glucose tolerance may not be mediated 
by an effect on hepatic glucose output. Since the hepatic 
response to oral and intravenous glucose differ, with significantly 
less splanchnic glucose uptake after an intravenous glucose load 
as compared to an oral glucose load (148), these findings do not 
eliminate the possibility that GH had an effect on hepatic glucose 
uptake. Finally, evidence from other studies suggests that GH 
causes decreased peripheral uptake of glucose by muscle and fat 
tissue (64, 83, 88). Since peripheral uptake by adipose and muscle 
cells accounts for the disposal of 15% of an oral glucose load, it 
might explain the decreased glucose tolerance observed in this study 
While earlier studies have reported increases in circulating 
FFA 2 to 4 hours after administration of pharmacologic doses of 
GH (80, 84-87), the effect of physiologic GH elevations have not 
previously been examined. Our findings indicate that the pattern 
of response is quite similar whether physiologic or pharmacologic 
doses are given, i.e. FFA begin to increase 2 hours after administra 
tion of GH to approximately 100% preinfusion values. In our 
studies, there was no evidence of an early hypolipademic effect, 
which supports the hypothesis of I'erimee and Rabin (10) that the 
insulin-like actions of GH previously reported (83-84) are only 
of pharmacologic, not physiologic, significance. The increase 
in FFA was clearly not due to hypoinsulinemia since insulin levels 
actually increased in the GH-infused subjects. Although this study 
did not address the question of the mechanism of this effect, 
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results of previous studies, utilizing pharmacologic doses of GH, 
suggest that GH acts directly on the adipocyte to increase lipolysis 
in a process that is dependent upon protein and RNA synthesis (69,73,75,86). 
With respect to the role of FFA in the glucose intolerance observed 
in this study, it has been suggested that elevations in circulating 
FFA levels may reduce glucose uptake by adipose and muscle tissue (149). 
However, other studies have found that inhibition of GH-induced 
lipolysis either does not prevent (87) or only partially prevents (86) 
GH-induced deterioration of glucose tolerance. In this study, FFA 
levels increased in the 2 subjects who did not exhibit deterioration of 
glucose tolerance to the same extent as in the 6 subjects who did 
demonstrate decreased glucose tolerance. It is unlikely, therefore, 
that elevated FFA levels accounted for the changes in glucose tolerance 
seen during treatment with GH. 
Blood ketone levels also increased during the infusion of GH. This 
might by secondary to GH-induced FFA elevations leading, in turn, to 
increased delivery of substrate (FFA) to the liver. In support of this 
hypothesis are the findings of Schade and Eaton(150) that elevations of 
blood FFA induced by heparin caused a prompt increase in blood ketone 
levels in normal subjects. Additional support it derived from the obser¬ 
vations of Heimberg et al. (151) that, in the perfused rat liver, ketone 
production is directly proportional to the concentration of FFA in the 
perfusate between 0 and 2.5 mM. Other workers, however, have presented 
evidence to show that increased hepatic delivery of FFA is necessary, 
but not sufficient, to cause increased hepatic ketone production 
(152), McGarry and Foster (153-154) postulated that, in addition 
to elevated blood FFA levels, hepatic ketogenesis must be 
stimulated, possible through the activation of carnitine acyl 
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transferase, the enzyme responsible for transport of fatty acids 
to the mitochondrial oxidative pathway. Furthermore, they suggest 
that elevations of plasma glucagon levels, or decreases in the 
insulin/glucagon ratio, regulate the ketogenic activity of the 
liver. In our study, glucagon levels decreased whereas the insulin/ 
glucagon ratio increased and, therefore, could not be responsible 
for augmenting hepatic ketogenesis. Our results do not exclude 
a direct effect of GH on hepatic ketogenesis and further studies 
will be needed in order to clarify this issue. Of interest in 
this regard, are studies suggesting that GH may increase ketosis 
in insulin-deficient diabetics by stimulating the ketogenic 
capacity of the liver and/or by decreasing ketone removal (89). 
Regardless of the mechanism involved, the elevated blood FFA and 
ketone levels induced by GH are consistent with the possibility 
that GH is a physiologically significant factor in the genesis of 
stress-induced elevations of FFA and ketone concentrations. 
In man, pharmacologic doses of GH cause a decrease lr. hicod 
amino nitrogen concentrations (129-131) and a decrease in the 
blood levels of several amino acids (133) within 30 to 60 minutes 
after administration of GH. In rats, large doses of GH cause 
increased uptake of many amino acids (119-120) and increased in¬ 
corporation of most amino acids into protein (120) in muscle and 
hepatic tissue within 30 to 60 minutes after exposure to GH. 
In contrast to this rapid, more generalized effect on amino acid 
metabolism, our data show that physiologic elevations of plasma 
GH levels result in a specific decrease in plasma alanine con- 
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centrations that is not apparent until 3 hours after initiation 
of GH treatment. We found no evidence of a generalized hypo- 
aminoacidemic action of GH which suggests that the results ob¬ 
served after administration of large doses of GH are a pharma¬ 
cologic, not physiologic, action of GH. 
Alanine is of particular importance as the major amino 
acid precursor utilized for hepatic gluconeogenesis and in 
normal postabsorptive subjects accounts for a minimum of 6% 
to 12% of hepatic glucose output (155). The glucose-alanine 
cycle describes the interorgan transfer of alanine. In brief, 
alanine is synthesized in muscle from glucose- derived pyruvate 
by transamination and released into the bloodstream where it is 
taken up by the liver and converted into glucose (155). The 
observed reduction in plasma alanine levels could be the 
result of either a decrease in alanine synthesis and output by 
muscle or an increase in herutir alanine uptake. Our data do 
not distinguish between these possibilities. However, in a study 
in which pharmacologic concentrations of GH were achieved (200 ng/ml), 
no effect on hepatic uptake of alanine was observed (107). Thus, 
it is unlikely that GH-induced changes in hepatic alanine uptake 
were the cause of the observed decrease in plasma alanine concentra¬ 
tion. 
Insulin is known to lower the blood concentrations of most 
amino acids, particularly the branch chained ones, due to an 
inhibition of their output from muscle (156). In contrast, insulin 
tends to increase the output of alanine from muscle due to an in¬ 
crease in the synthesis of alanine from glucose (155). Since no 

significant changes in the concentration of other amino acids 
were observed in this study and since insulin tends to increase 
alanine synthesis in muscle, it is unlikely that the decrease in 
alanine seen in this study is explained by the elevated plasma 
insulin levels in the GH-treated subjects. 
It is possible that the decrease in plasma alanine concen¬ 
tration was not a direct consequence of GH action on amino acid 
metabolism. Sherwin et al#(157) have shown that infusion of 
ketones for 3 hours into normal postabsorptive subjects results 
in a 217 ine in plasma alanine levels without significantly 
effecting the concentrations of other amino acids. The steady 
state concentration of ketones achieved in that study is similar 
to the concentration observed at the end of the basal period 
in the present study. Alanine was noted to decrease significantly 
by 90 minutes after the start of the ketone infusion. In the 
present study, FFA levels were significantly elevated by 180 
minutes, whereas alanine levels did not significantly decrease 
until 240 minutes after the start of the GH infusion. Thus, 
our data are consistent with the possibility that the decrease 
in plasma alanine may be due to an increase in ketones. Additions 
studies will be needed to determine if the fall in plasma alanine 
is a direct effect of GH or a secondary consequence of changes in 
other substrates of hormones, e.g. ketones. 
Our studies indicate that physiologic doses of GH produce 
a rapid, albeit small, increase in basal insulin concentration 
and a marked increase in glucose-stimulated insulin secretion. 
Similar findings have previously been reported in situations of 
chronic GH excess, such as acromegaly (55,57,61-62), and after 
administration of pharmacologic amounts of GH (62,64-65,106). 

Adamson et al, however, have reported an acute decrease 
in basal and glucose-stimulated insulin secretion after 
infusion of physiologic quantities of GH (109,113-114). 
It is difficult to reconcile their findings with our own and 
with most of the rest of the literature. 
The occurrence of increased FFA and ketone levels 
and the deterioration of glucose tolerance in the face of 
elevated plasma insulin concentration, suggests that GH may 
have induced a state of insulin resistance. Chronic GH excess 
(53-54, 63-65) and acute exposure to pharmacologic doses 
of GH (64-65,89) have previously been shown to induce insulin 
resistance. Our results suggest that GH-induced insulin resis¬ 
tance can occur rapidly after physiologic elevations of GH 
levels. 
One possible mechanism of GH-induced insulin resistance is 
the presence of changes in the insulin receptor, since insulin, 
like other peptide hormones, must bind to a specific receptor 
on the cell membrane in order to be effective. The importance 
of changes in the receptor is emphasized by the many studies 
showing corresponding changes in the insulin receptor and in 
insulin sensitivity. For example, insulin binding and insulin 
sensitivity are both decreased in obesity (158-160), maturity 
onset diabetes (161—162), uremia (162), and in patients with 
idiopathic GH deficiency after treatment with GH (163). Con¬ 
versely, insulin sensitivity and insulin binding are both in¬ 
creased in anorexia nervosa (164-165) and in idiopathic GH 
deficiency (163). This correlation is not universal, however, 
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since opposite changes occur in binding and insulin 
sensitivity in starvation (160), pregnancy (166) and 
states of high carbohydrate intake (167). 
It is not clear exactly what role the insulin receptor 
plays in GH-induced insulin resistance. In rats, Kahn 
et al. (102) found that 5 days of treatment with pharma¬ 
cologic doses of GH caused a slight decrease in number and 
and increase in affinity of the hepatocyte insulin receptor. 
Since the net result was normal insulin binding at basal 
insulin levels, they concluded that on exerted its anti¬ 
insulin actions at a site distal to the insulin receptor. 
Muggeo et al.(66) similarly found a decreased receptor con¬ 
centration and an increased receptor affinity in monocytes 
taken from acromegalic patients. These changes resulted in 
normal binding of insulin at basal insulin concentrations 
and decreased insulin binding at high plasma insulin levels. 
Since many patients with acromegaly have elevated fasting and 
glucose-stimulated insulin levels (55-61), the insulin receptor 
might contribute, at least in part, to the insulin resistance 
of acromegaly. Not all situations of GH excess are associated 
with decreased insulin sensitivity and decreased insulin 
binding. Patients with anorexia nervosa, for example, exhibit 
elevated plasma GH levels, increased insulin sensitivity and 
increased insulin binding (164-165). 
The presence of alterations in insulin binding characteristics 
and GH excess do not necessarily imply that GH exerts a direct 
effect on the insulin receptor. Insulin has been shown to 

modulate its own receptor both in vitro (168) and in vivo (169). 
Thus, GH could cause decreases in insulin binding by one of 
several mechanisms. It could act directly on the insulin 
receptor, it could block insulin action at a site distal to the 
receptor, leading, in turn, to hyperinsulineraia and subsequent 
insulin-induced receptor changes, or it could directly stimulate 
insulin secretion with insulin secondarily modifying the 
insulin receptor so as to cause insulin resistance. 
In order to see if GH excess acutely effected the insulin 
receptor, we measured insulin binding to monocytes and erythro¬ 
cytes at G and 4 hours after the start of the GH infusion. 
This work was done in collaboration with Dr. Vijay Soman. Pre¬ 
liminary results are described in Table 7. They show that 
specific binding of insulin to erythrocytes decreased by 16% 
(0 hours, 7.7 ± 1.1% vs 4 hours, 6.5 ± 1.0%, p<0.01), whereas 
in-uMr, l-’nding to monocytes increased by 45% (0 hours, 10.9 ± 0.9% 
VS 4 hours, 15.5 ± 1.6%). Since only 3 patients were studied, the 
monocyte data do not reach statistical significance. Pre¬ 
liminary analysis of the binding curves by Dr. Soman suggests 
that the decrease in insulin binding to erythrocytes is pri¬ 
marily due to a decrease in receptor affinity, whereas the 
increase in insulin binding to monocytes is mainly due to an 
increase in receptor affinity, not receptor number. 
While very preliminary, these results are the first study in 
man in which insulin binding was found to decrease in one and 
increase in another cell type. Previous studies have found that 
insulin binding to both erythrocytes and monocytes decreases 
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nervosa (164-165). If further studies confirm these results, then 
the relationship of insulin binding to elements of peripheral blood 
to insulin binding on insulin-responsive cells such as adipocytes 
and hepatocytes must by carefully examined. If the monocyte data 
is indeed representative of the binding changes on insulin-responsive 
tissue, then it is unlikely that alterations in insulin binding 
can account for the observed increase in insulin resistance 
induced by acute exposure to physiologic increments of GH. 
CONCLUDING STATEMENT 
It has been postulated that GH has two different types of 
effects on glucose and fat metabolism: 1) an acute insulin-like 
effect and 2) an anti-insulin like action seen after longer term 
exposure to GH. Our results suggest that acute elevations of plasma 
GH concentrations, to levels normally seen during severe stress, 
do "of ct"se any insulin—like effects and imply that the acute 
xnsulin-like actions of GH are a pharmacologic, not physiologic, effect. 
Furthermore, these data show that the anti-insulin actions of GH 
can occur within a few hours after exposure to GH. These findings 
are consistent with the possibility that acute elevations of plasma 
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